Raxone (also known as Idebenone) is a drug produced by Santhera Pharmaceuticals, which treats several conditions and has the potential to treat Duchenne muscular dystrophy. It is presently available in the UK on the Early Access to Medicines Scheme for patients who meet the criteria.

In partnership with fellow organisations, Muscular Dystrophy UK, Duchenne UK, the Duchenne Family Support Group, and DMD Pathfinders, we have produced two guides for families and healthcare professionals to educate and answer questions on the drug and EAMS process.


Raxone_- A Guide for our Community.pdf

Raxone_-_A Guide for Clinicians.pdf

If you have any follow up questions on Raxone, or the EAMS process, please email our Director of Campaigns & Strategy on [email protected], or call our office directly on 02072508240.